Ethical Holdings' 2nd Qtr Results

23 April 1997

- Ethical Holdings reported a net loss of L2.5 million ($4 million),or L0.17 per share, for the second quarter of 1997, an increase over the same period in 1996 in which the group posted a net loss of L1.3 million, or L0.09 per share. This is due, it says, to a 20% increase in R&D costs to L5.5 million, plus interest payable and higher-than-expected losses from associate companies. The operating loss was L2.7 million versus L3 million in same-period 1996. Revenues were up 29% to L6.3 million for the year to date.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight